Matches in DBpedia 2016-04 for { ?s ?p "Pegloticase (trade name Krystexxa, formerly Puricase) is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals.In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Pegloticase comment "Pegloticase (trade name Krystexxa, formerly Puricase) is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals.In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.".
- Q7160794 comment "Pegloticase (trade name Krystexxa, formerly Puricase) is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals.In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.".